SymBio raises $24 mn to advance bendamustine and other pipeline projects
This article was originally published in Scrip
Executive Summary
The Japanese venture SymBio Pharmaceuticals has raised ¥2.0 billion ($24 million) in a Series E financing led by two major existing investors, Cephalon and the Japanese private equity firm JAFCO.